Amgen Inc. (AMGN) key performance indicators and operating metrics (20 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP operating margin | 45.30 percent | FY2026-Q1 |
| Non-GAAP operating income | 3.7B | FY2026-Q1 |
| Non-GAAP EPS | 5.15 USD_per_share | FY2026-Q1 |
| Total product sales | 8.22B | FY2026-Q1 |
| Free cash flow (Free Cash Flow) | 1.5B | FY2026-Q1 |
| Product sales - U.S. | 5.77B | FY2026-Q1 |
| Product sales - ROW | 2.45B | FY2026-Q1 |
| Prolia sales | 727M | FY2026-Q1 |
| Repatha sales | 876M | FY2026-Q1 |
| Product sales volume growth | 9.00 percent | FY2026-Q1 |
| TEPEZZA sales | 490M | FY2026-Q1 |
| Otezla | 618M | FY2025-Q2 |
| Prolia | 1.12B | FY2025-Q2 |
| Repatha | 696M | FY2025-Q2 |
Back to AMGN overview · AMGN earnings · AMGN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.